Alzheimer's DiseaseSENS-eADNCT07138677
Safty and Efficacy of MCI Network Guided TMS for Early Alzheimer's Disease: A Randomized, Double-blind Trial
A study testing transcranial magnetic stimulation in people with Alzheimer's Disease and Transcranial Magnetic Stimulation, run by Anhui Medical University at 1 site in China.
Trial summary
Estimate the safty and efficacy of personalized network neuronavigated transcranial magnetic stimulations in early Alzheimer's disease patients Read more about this study
- Who is it for?
- Ages 45 to 85 years
- Conditions the study is for
- Alzheimer's Disease, Transcranial Magnetic Stimulation, Individualized Navigation
- What is being tested?
- transcranial magnetic stimulation
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteChina
- Study dates
- 20 Jul 2025to 14 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject diagnosed as either mild cognitive impairment due to AD or mild AD dementia based on National Institute on Aging-Alzheimer's Association criteria.
- MMSE score 18-28.
- CDR score 0.5-1.
- On stable treatment with IAChE or memantine for at least 6 months.
- Literate in Han Chinese.
Who cannot join
- Recevied rTMS treatment in the past 3 months.
- Depression or other psychiatric disorders.
- History of head injury, stroke, epilepsy or other neurologic disease.
- Organic brain defects on T1 or T2 images.
- History of unexplained loss of consciousness.
- Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, or any implanted medical device that is incompatible with MRI.
- Family history of medication refractory epilepsy.
- History of substance abuse within the last 6 months.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Safty and Efficacy of Mild Cognitiive Impairment Network Guided Transcranial Magnetic Stimulations for Patients With Early Alzheimer's Disease (SENS-eAD): A Randomized, Double-blind Trial
Estimate the safty and efficacy of personalized network neuronavigated transcranial magnetic stimulations in early Alzheimer's disease patients
Read the detailed description
All patients undergo a series of medical assessments that include physical examination and routine laboratory studies before and after repetitive transcranial magnetic stimulation (rTMS) treatment. Upon meeting the inclusion criteria and providing informed consent, each participant will complete a series of cognitive assessments and rTMS treatments at the First Affiliated Hospital of AnHui medical university. Stratified block randomization will be used to assign participants to different intervention groups. Stratification is based on Mini-Mental State Examination (MMSE) scores (<24 vs. ≥24), and randomization will be conducted using variable block sizes of 4 or 6.
For each participant, the investigators will compute their persoanlized dorsal prefrontal targets by using their own resting-state functional MRI data and a predefined MCI network. They will then be randomly assigned to receive real or sham rTMS treatment for two weeks. The sham stimulations will be delivered by a sham coil. All the experiment procedures are the same between groups except the coil.
With a statistical power of 0.8, an effect size of 0.96, a significance level of 0.05, and a 5% expected dropout rate, the final sample size is 20 participants per group. In this double-blind study, patients and clinical raters are masked to the allocated conditions. Only one investigator responsible for group allocation has access to the randomization list.
Each participant will be treated for 14 days by rTMS. Before the rTMS treatment, a trained investigator will perform a series of cognitive assessments and neuropsychological tests. The ADAS-Cog is the primary outcome. Other tasks and questionnaires include cognition (including MoCA, MMSE, DS, Stroop test, BNT-30, VFT, CDT, JLOT. Form H, HVOT), memory (CAVLT, LMT), emotion (HAMA-17,HAMD-14), behavioral and psychological symptoms (NPI), and treatment tolerability. All the tests will be conducted within two days. The participants undergo a multi-modal MRI scan and an electroencephalogram (EEG) examination.
The participants also undergo the ADAS-cog, a battery of neuropsychological tests, multi-modal MRI, and EEG examinations. participants will be instructed to focus their answers on the past 14 days.
- Being tested
- transcranial magnetic stimulation
- Keywords
- Alzheimer's Disease, Transcranial Magnetic Stimulation, Individualized navigation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
transcranial magnetic stimulationOther
Neuronavigated Theta-Burst Transcranial Magnetic Stimulation
| Study group | Role | What they receive |
|---|---|---|
| MCI real group | Experimental | Stimulation delivered by a real coil through MagStim Rapid2 and guided by BrainSight navigation system. Receives: Other: transcranial magnetic stimulation |
| MCI sham group | Sham comparator | Stimulation delivered by a sham coil through MagStim Rapid2 and guided by BrainSight navigation system. Receives: Other: transcranial magnetic stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Alzheimers Disease Assessment Scale Cognitive section (ADAS-Cog)
The changes in Alzheimers Disease Assessment Scale Cognitive section (ADAS-Cog) will constitute the major research outcome measure used to assess response to transcranial magnetic stimulation (TMS). The ADAS-COG scale tests orientation, language, structure, use of ideas, immediate recall of words and word re-recognition, and consists of 11 questions out of a possible 70 points, with the higher the score the more cognitively impaired.
Measured: Baseline and 2 weeks
Secondary outcomes (12)
Mini Mental State Examination (MMSE)
The changes in MMSE will constitute the primary research outcome. The full name of MMSE is mini-mental state examination, and the scale consists of 30 subject, include the following seven aspects: time orientation, place orientation, immediate memory, attention and calculation, delay memory, language, visual space. One point is awarded for each question correctly answered during MMSE evaluation. If subject give the wrong answer or don't know answer he/she awarded 0 score, scope of scale score of 0 to 30 points. The higher the score, the better. In this study, changes in MMSE scores before and after treatment were used as secondary outcome measure.
Measured: Baseline and 2 weeks
Montreal Cognitive Assessment (MoCA)
The changes in MoCA will be used to assess the response to TMS. MoCA was developed by Nasreddine et al. based on clinical experience and reference to the MMSE cognitive items and scores, and the final version was finalized in November 2004. The investigators adopted a localized version (Mandarin version#includes 2 alternative versions) in line with the Chinese cultural background. It includes 11 inspection items in 8 cognitive fields, including visual structure skills, executive function, naming, attention and calculation, language, abstract thinking, memory, and orientation. The normal score range from 26 to 30. Anyone who has been education for less than 12 years will need to add one point to his final score. The final score of the higher the better.
Measured: Baseline and 2 weeks
Digital Span Test; Forward and Backward (DST)
The changes in DST will constitute the secondary research outcome. Digital span test (DST) was commonly used to evaluate attention ability and instantaneous memory ability. There are two types of test: forward (0-14) and backward (0-13). In the forward test, the subjects were asked to retell the the digits immediately after hearing it untilthey could not be repeated correctly. In backward test, the subjects were asked to repeat a set of numbers in reverse order until they could not be repeated correctly. The length of the last set of Numbers correctly repeated by the subjects was the final score, forward and backward are counted separately. The higher the score, the better.
Measured: Baseline and 2 weeks
Hamilton Depression Scale (HAMD)
Hamilton Depression Scale (HAMD) compiled by Hamilton in 1960, is the most common clinical to assess Depression Scale. In this study, we selected the HAMD version with 17 questions. Subjects were assessed for their depression in the past week. Each question scored between 0 and 4 points. Higher scores indicate more depressive symptoms. The severity of the disease and the therapeutic effect can be evaluated after treatment.
Measured: Baseline and 2 weeks
Hamilton Anxiety Scale (HAMA)
Hamilton Anxiety Scale (HAMA) was compiled by Hamilton in 1959. It was one of the most commonly used scales in psychiatric clinic, including 14 items. It is often used in clinical diagnosis and degree classification of anxiety disorder. The subjects were assessed for their anxiety in the past week. Each question scored between 0 and 4 points. The higher the score, the more symptoms of anxiety.
Measured: Baseline and 2 weeks
Neuropsychiatric Inventory (NPI)
The Neuropsychology Scale (NPI) evaluates 12 neuropsychiatric disorders which included 10 neuropsychiatric symptoms and 2 autonomic neurological symptoms based on the caregiver's perception of the patient's behavior and the perceived distress. Each item was evaluated for its occurrence frequency (1-4 points) and severity (1-3 points). The frequency and severity were multiplied to obtain the score (0-12 points) of each item.The patient's assessment rating ranges from 0 to 144, and the caregiver's distress rating score is 0 to 60. The lower the score, the lighter the symptoms.
Measured: Baseline and 2 weeks
Judgment of line Judgment of line orientation test (JLOT)
The JLOT test was determined by Benton et al. in 1994. There are two versions of H and V. The difference is that the order in which the pictures are presented is different. Each version contains 35 images, of which the official test consists of 30 images, and the other 5 images are for the participants to learn. The final score is the correct number of subjects to answer, the full score is 30 points, the higher the score, the better the space perception ability of the subject.
Measured: Baseline and 2 weeks
Hooper visual organization test (HVOT)
HVOT is a cognitive test used to evaluate the perceived structure of the subject. It consists of 30 items (1 point each question) and the total score is 30 points. The final score is the correct number of subjects to answer, the full score is 30 points. The higher the score, the better the space perception ability of the subject.
Measured: Baseline and 2 weeks
The Stroop color word test
The Stroop color word test was developed by Stroop in 1935 and is used to evaluate the attention function of the subject. The subject is required to correctly read the target color on the stimulus card and record the completion time. The final completion time is the score of the participant. The shorter the time used, the better the performance of the subjects.
Measured: Baseline and 2 weeks
EEG
EEG data were obtained from each subject based on 64 electrode locations of the International 10-20 system (sampling frequency 1000Hz).
Measured: Baseline and 2 weeks
Logic Memory Test (LMT)
The Logical Memory test, part of the Wechsler Memory Scale, primarily assesses an individual's verbal memory capabilities. The test involves presenting two brief stories to the subject, who is then asked to immediately recall and subsequently recall them after a delay. By comparing the immediate and delayed recall performance, the subtest evaluates both short-term and long-term memory retention.
Measured: Baseline and 2 weeks
Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is a standardized tool used to assess individual sleep quality. It consists of 19 self-rated items that evaluate sleep quality, covering 7 aspects including sleep duration, efficiency, disturbances, and others. Each component is scored from 0 to 3, with higher scores indicating poorer sleep quality.
Measured: Baseline and 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Aug 2025
- Study start20 Jul 2025
- Primary completion14 Mar 2026
- Study completion14 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer's DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Anhui Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, WANG KAI, Anhui Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07138677
- Sponsor's protocol ID
- AHMU-NetTMS-eAD
- Acronym
- SENS-eAD
- Status last verified
- Jun 2026
- First submitted
- 30 Apr 2025
- Last updated
- 12 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Safty and Efficacy of Mild Cognitiive Impairment Network Guided Transcranial Magnetic Stimulations for Patients With Early Alzheimer's Disease (SENS-eAD): A Randomized, Double-blind Trial
- ClinicalTrials.gov ID
- NCT07138677
- Acronym / sponsor ID
- SENS-eAD / AHMU-NetTMS-eAD
- Keywords
- Alzheimer's Disease, Transcranial Magnetic Stimulation, Individualized navigation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Anhui Medical UniversityUniversity, hospital or other
- Study start
- 20 Jul 2025 (actual)
- Primary completion
- 14 Mar 2026 (actual)
- Study completion
- 14 Apr 2026 (actual)
- First posted
- 24 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Estimate the safty and efficacy of personalized network neuronavigated transcranial magnetic stimulations in early Alzheimer's disease patients
Detailed description
All patients undergo a series of medical assessments that include physical examination and routine laboratory studies before and after repetitive transcranial magnetic stimulation (rTMS) treatment. Upon meeting the inclusion criteria and providing informed consent, each participant will complete a series of cognitive assessments and rTMS treatments at the First Affiliated Hospital of AnHui medical university. Stratified block randomization will be used to assign participants to different intervention groups. Stratification is based on Mini-Mental State Examination (MMSE) scores (<24 vs. ≥24), and randomization will be conducted using variable block sizes of 4 or 6.
For each participant, the investigators will compute their persoanlized dorsal prefrontal targets by using their own resting-state functional MRI data and a predefined MCI network. They will then be randomly assigned to receive real or sham rTMS treatment for two weeks. The sham stimulations will be delivered by a sham coil. All the experiment procedures are the same between groups except the coil.
With a statistical power of 0.8, an effect size of 0.96, a significance level of 0.05, and a 5% expected dropout rate, the final sample size is 20 participants per group. In this double-blind study, patients and clinical raters are masked to the allocated conditions. Only one investigator responsible for group allocation has access to the randomization list.
Each participant will be treated for 14 days by rTMS. Before the rTMS treatment, a trained investigator will perform a series of cognitive assessments and neuropsychological tests. The ADAS-Cog is the primary outcome. Other tasks and questionnaires include cognition (including MoCA, MMSE, DS, Stroop test, BNT-30, VFT, CDT, JLOT. Form H, HVOT), memory (CAVLT, LMT), emotion (HAMA-17,HAMD-14), behavioral and psychological symptoms (NPI), and treatment tolerability. All the tests will be conducted within two days. The participants undergo a multi-modal MRI scan and an electroencephalogram (EEG) examination.
The participants also undergo the ADAS-cog, a battery of neuropsychological tests, multi-modal MRI, and EEG examinations. participants will be instructed to focus their answers on the past 14 days.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MCI real group | Experimental | Other: transcranial magnetic stimulationStimulation delivered by a real coil through MagStim Rapid2 and guided by BrainSight navigation system. |
| MCI sham group | Sham comparator | Other: transcranial magnetic stimulationStimulation delivered by a sham coil through MagStim Rapid2 and guided by BrainSight navigation system. |
Who may qualify
- Ages
- 45 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Subject diagnosed as either mild cognitive impairment due to AD or mild AD dementia based on National Institute on Aging-Alzheimer's Association criteria.
- MMSE score 18-28.
- CDR score 0.5-1.
- On stable treatment with IAChE or memantine for at least 6 months.
- Literate in Han Chinese.
Key exclusion criteria (8 listed)
- Recevied rTMS treatment in the past 3 months.
- Depression or other psychiatric disorders.
- History of head injury, stroke, epilepsy or other neurologic disease.
- Organic brain defects on T1 or T2 images.
- History of unexplained loss of consciousness.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| transcranial magnetic stimulationNeuronavigated Theta-Burst Transcranial Magnetic Stimulation | Other | MCI real group, MCI sham group |
Primary outcome
Alzheimers Disease Assessment Scale Cognitive section (ADAS-Cog)
Time frame: Baseline and 2 weeks
The changes in Alzheimers Disease Assessment Scale Cognitive section (ADAS-Cog) will constitute the major research outcome measure used to assess response to transcranial magnetic stimulation (TMS). The ADAS-COG scale tests orientation, language, structure, use of ideas, immediate recall of words and word re-recognition, and consists of 11 questions out of a possible 70 points, with the higher the score the more cognitively impaired.
12 secondary outcomes
Mini Mental State Examination (MMSE)
Time frame: Baseline and 2 weeks
Montreal Cognitive Assessment (MoCA)
Time frame: Baseline and 2 weeks
Digital Span Test; Forward and Backward (DST)
Time frame: Baseline and 2 weeks
Hamilton Depression Scale (HAMD)
Time frame: Baseline and 2 weeks
Hamilton Anxiety Scale (HAMA)
Time frame: Baseline and 2 weeks
Neuropsychiatric Inventory (NPI)
Time frame: Baseline and 2 weeks
Judgment of line Judgment of line orientation test (JLOT)
Time frame: Baseline and 2 weeks
Hooper visual organization test (HVOT)
Time frame: Baseline and 2 weeks
The Stroop color word test
Time frame: Baseline and 2 weeks
EEG
Time frame: Baseline and 2 weeks
Logic Memory Test (LMT)
Time frame: Baseline and 2 weeks
Pittsburgh Sleep Quality Index (PSQI)
Time frame: Baseline and 2 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Alzheimer's Disease
RecruitingObservational study
Speech and Language Interventions for Italian People With PPA
Primary Progressive Aphasia(PPA)
Active, not recruitingPhase 1/2
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
Alzheimer's Disease (AD)
Not yet recruiting
Novel Brain Stimulation Treatment for Neuropsychiatric Symptoms in Alzheimer's Disease
Alzheimer&Amp;#39;s Disease-related Dementia, Alzheimer Disease
RecruitingPhase 1
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
Alzheimer Disease, Alzheimer Disease (AD)
RecruitingObservational study
Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
Alzheimer's Disease (AD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing transcranial magnetic stimulation in people with Alzheimer's Disease and Transcranial Magnetic Stimulation, run by Anhui Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Alzheimers Disease Assessment Scale Cognitive section (ADAS-Cog) (time frame: Baseline and 2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2026.